Matthew Reaney joins ERT as a scientific and regulatory consultant
As a Senior Scientist, Matt brings to ERT a wealth of first-hand experience in designing, implementing, and leveraging COAs – with considerable focus on Patient Reported Outcomes (PROs) – in drug development and in clinical practice. He has in-depth knowledge of current trends in the regulatory, payer and healthcare environments that affect COA research.
